12:00 AM
 | 
Nov 02, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tykerb lapatinib regulatory update

GlaxoSmithKline submitted an sNDA to FDA for Tykerb lapatinib to treat inflammatory breast cancer. The HER1 and

Read the full 83 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >